Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SCD | O00767 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL629896 | 0.86 | LMNA (0.65) | LMNAKDM4ESMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL10029587 | 0.82 | LMNA (0.59) | LMNAKDM4ESMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL627651 | 0.80 | LMNA (0.59) | LMNAKDM4ESMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL628055 | 0.80 | LMNA (0.60) | LMNAKDM4ESMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL628118 | 0.80 | LMNA (0.60) | LMNAKDM4ESMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL628096 | 0.79 | KDM4E (0.64) | LMNAKDM4ESMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL628071 | 0.78 | LMNA (0.53) | LMNAKDM4ESMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL629099 | 0.77 | KDM4E (0.74) | LMNAKDM4ESMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL628748 | 0.75 | LMNA (0.53) | LMNAKDM4ESMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL628808 | 0.75 | LMNA (0.41) | LMNAHPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077854-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | IRM LLC (BM) | 2012-03-29 | — | — | US | disclosed |
| US-20120077854-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | IRM LLC (BM) | 2012-03-29 | — | — | US | disclosed |
| EP-2419412-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | IRM LLC (BM) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010120741-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | IRM LLC (US) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077854-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | RBP4, RBP1, FABP4 | LMNA 1913/4885KDM4E 751/4885SMN1; SMN2 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.